|
N.S. Besova, E.S. Obarevich, A.A. Tryakin, D.A. Gavrilova, S.N. Nered, A.E. Kalinin, I.S. Stilidi
Conversion therapy for disseminated gastric cancer. Interim results of a retrospective analysis of our own data
|
№11 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, S.S. Ereshchenko, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Analysis of the effectiveness of various neoadjuvant chemotherapy regimens in patients with T1-3N1-3M0 I–IIIC stage locally advanced breast cancer
|
№6-7 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, T.Yu. Semiglazova, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
|
№6-7 / 2023
|
|
Ya.A. Yakimenko, V.V. Kutukov, V.V. Antonyan, M.A. Gaziev
Gastrointestinal toxicity during therapy with 5-fluorouracil
|
№6-7 / 2023
|
|
N.S. Besova
Conversion therapy for stage IV gastric cancer: a review of prognostic factors and patient selection criteria according to the literature data
|
№6-7 / 2023
|
|
V.F. Semiglazov, P.V. Krivorotko, T.Yu. Semiglazova, A.V. Komyakhov, T.T. Tabagua, M.D. Kazantseva, E.K. Zhiltsova, D.G. Ulrikh, M.V. Chervyak, A.P. Tergoeva, V.V. Klimenko, V.V. Semiglazov
Ixabepilone in the treatment of breast cancer
|
№11-12 / 2022
|
|
I.V. Poddubnaya, N.A. Ognerubov, T.S. Antipova
Thymus hyperplasia after lymphoma drug therapy: the role of PET/CT
|
№7 / 2022
|
|
O.D. Guryeva, M.I. Savelyeva, T.T. Valiev
Influence of pharmacogenetic parameters on clinical variants of methotrexate toxicity in acute lymphoblastic leukemia in children
|
№7 / 2022
|
|
M.M. Konstantinova (1), L.I. Kuzina (2)
Will our clinical practice change with the availability of new diagnostic methods, drug therapy and assessment of its effectiveness? Clinical case: hormone receptor-positive, HER2-negative metastatic breast cancer
|
№11 / 2021
|
|
S.V. Khokhlova
Clinical case of treatment of patient with HRD-positive ovarian cancer
|
№11 / 2021
|
|
T.Yu. Semiglazova (1, 2), Yu.V. Alekseeva (1), E.V. Tkachenko (1), S.M. Sharashenidze (1), I.A. Baldueva (1), S.A. Volchenkov (1), A.K. Kovyazin (1), L.V. Filatova (1, 2), B.S. Kasparov (1), V.V. Semiglazov (1, 3), S.A. Protsenko (1), V.N. Anisimov (1), A.M. Belyaev (1, 3)
Features of examination and systemic treatment of malignant neoplasms in gerontological patients
|
№7 / 2021
|
|
G.G. Khakimova (1, 2), A.A. Tryakin (3), T.N. Zabotina (3)
Dynamics of indicators of systemic and local immunity during treatment in patients with gastric cancer
|
№7 / 2021
|
Русский
